A Study to Assess 7/8 HLA-matched Hematopoietic Stem Cell Transplantation Participants Treated With or Without Abatacept in Combination With a Calcineurin Inhibitor and Methotrexate

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
The purpose of this study is to estimate overall survival (OS) for participants treated with abatacept versus those not treated with abatacept prior to hematopoietic stem cell transplantation (HSCT). Participants were included if their donors were unrelated and had 1-allele mismatched human leukocyte antigen (HLA) status.
Epistemonikos ID: 45bb3f72cecc22fab20c902314fcbb04bc43f1d0
First added on: May 13, 2024